ILA

ILA is positioning galidesivir as a broad-spectrum filovirus countermeasure against a critical unmet need—no approved therapeutics exist for Marburg, Bundibugyo, or Sudan strains, and current Ebola countermeasures are strain-specific. The May–July 2026 Bundibugyo outbreak (1,582 cases, 508 deaths) and WHO emergency declaration create timely regulatory and commercial urgency for a multi-strain antiviral.

Island has secured WHO-recognised MEURI approvals to deploy Galidesivir for compassionate use in the active Bundibugyo Ebola outbreak in Uganda, enabling prospective human efficacy and safety data collection in a setting where no approved therapies exist. The government-funded, non-dilutive programme leverages prior 100% NHP survival data and positions the drug toward biodefence procurement and broader commercialisation.

Island Pharmaceuticals secured Singapore patent protection for ISLA-101 covering Dengue and Chikungunya through 2034, strengthening IP exclusivity in a key Asia-Pacific region with high disease prevalence. This is a routine patent milestone that supports future partnering and commercialisation but does not advance clinical development or revenue generation.